我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

重组生长激素治疗扩张型心肌病的初步研究(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2002年第4期
页码:
307-309
栏目:
临床研究
出版日期:
2002-07-01

文章信息/Info

Title:
A preliminary study recombinant growth hormone in treatment of dilated cardiomyopathy
作者:
蓝景生1;  王晋明2
1.广西右江民族医学院附院心内科, 广西 百色 533000; 2.湖北医科大学附属第一医院心内科
Author(s):
LAN Jing-sheng ; WANG Jin-ming
Department of Cardiology, the Affiliated Hospital of You Jiang Medical College for Nationalities,Baise, Guangxi 533000, China
关键词:
心肌病;  扩张型;  重组生长激素;  临床试验
Keywords:
dilated cardiom yopathy;  recom binant growth hormone;  clinical trial
分类号:
Q575.11; R542.2
DOI:
-
文献标识码:
A
摘要:
目的 进一步评价重组生长激素(r2GH) 治疗中、晚期扩张型心肌病(DCM) 的临床疗效。方法 13 例中晚期DCM 在强心、利尿、扩管治疗的基础上接受r2GH 皮下注射, 在基础治疗3 个月前后及r2GH 治疗3 个月后测定其血中三碘甲状腺原氨酸(T3)、四碘甲状腺原氨酸(T4)、促甲状腺素(TSH)、生长激素(GH)、62酮2前列腺素F1A(62keto2PGF1A) 浓度、患者的基本状况、心胸比率以及超声参数, 采用自身对照进行比较, 同时观察r2GH 的副作用。结果 ①基础治疗3个月后, 患者体重、心率、血压、N YHA 心功能评级、心胸比率的变化与治疗前相比, 无统计学意义(P > 0. 05)。r2GH 治疗后心率、N YHA 心功能分级、心胸比率均降低(分别为P < 0.01, P < 0101, P < 0.05)。②r2GH 治疗后血中T3, GH, 62keto2PGF1A升高(分别为P < 0.05, P < 0.01, P < 0.01)。③r2GH 治疗后心脏各腔室内径缩小, 均有统计学意义(均为P < 0.05) , 左心室质量及左室射血分数增加, 均有统计学意义(均为P < 0.05)。结论 r2GH 治疗中、晚期DCM 有较好疗效, 无明显不良反应。推广临床应用还应进一步观察。
Abstract:
AIM To investigate the effect of recombinant growth hormone(r-GH) therapy for dilated cardiomyopathy(DCM).METHODS 13 patients with moderate-to-late stage DCM were studies at base line after three months of conventional therapy and three months of r-GH treatment.Thyroid hormone, growth hormone and prostacyclin were determined with immuoassay, and the heart-thorax ratios were measured on chest x-ray. Heart ultrasonic parameters were measured with echocardiography. Results were analysed with SPSS.RESULTS ①After three months of conventional therapy, no statistic significance was found in the changes of NYHA class,the heart-thorax ratios and heart rate(P>0.05). After three months of r-GH therapy,the parameters decreased(P<0.01 orP<0.05).②After three months r-GH therapy, the levels of T3,GH,6-keto-PGF1αwere much higher than the levels of this hormone at basic line and before r-GHtherapy (P<0.05,P<0.01,P<0.01)。③After three months r-GHtreatment, the size of dilated chambers reduced(P>0.05),EF and LVM increased(P<0.05,P<0.05). CONCLUSION r-GH treatment is effective in moderate-to-late stage DCM.

参考文献/References

[1] Fazio S,Sabatina D,Capalado B,et al. A preliminary study of growth hormone in treatment of dilated cardiomyopathy[J].N Engl J Med,1996,34(13):809-814.

[2] Osterziel KJ, Naokus U, Willenbrock R,et al. Therapy of dilated cardiomyopathy with recombinant human growth hormone[J].Z Cardiol,1997,86(10):803-811.

[3] Lombardi G,Colao A,Ferone D,et al. Effect of growth hormone on cardial function[J].Horm Res,1997,48(Supp C4):38-42.

[4] Grunfeld C,Sherman BM,Cavalieri RR. The acute effects of human growth hormone adiministration on thyroid function in normal man[J].J Clin Endocrinol Metab, 1988, 67: 1111 -1114.

[5] Johansson JO,Landin K,Tengborn L,et al. High fibrinogen and plasminogen activator inhibitor activity in growth hormone deficient adults[J].Arterioscler Thromb,1994,14:434-437.

[6] Hasefass G,Mulieri LA,Leavitt BJ,et al. Contractile protein function in failing and unfailing human myocardium[J].Basie Res,Cardiol,1992,87:107-116.

[7] Osterziel KJ,Strohm O,Shuler J,et al. Randomized double-blind, placebo-Controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy[J] . Lancet, 1998,351:1233-1237.

[8] O′Driscod JG,Green DJ,Ireland M,et al. Treatment of end-stage cardial fairlure with growth hormone[J].Lancet,1997, 349:1068.

备注/Memo

备注/Memo:
收稿日期：2001-03-20.
更新日期/Last Update: 2002-07-01